🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Mario Gabelli’s APLS Holdings & Trades

First Buy
Q1 2026
Duration Held
1 Quarters
Largest Add
Q1 2026
+21,000 Shares
Current Position
21,000 Shares
$844,830 Value

Mario Gabelli's APLS Position Overview

Mario Gabelli (via Gamco Investors, Inc. Et Al) currently holds 21,000 shares of Apellis Pharmaceuticals, Inc. (APLS) worth $844,830, representing 0.01% of the portfolio. First purchased in 2026-Q1, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Mario Gabelli has initiated a new position in APLS, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Mario Gabelli's Apellis Pharmaceuticals (APLS) Holding Value Over Time

Track share changes against reported price movement

Quarterly Apellis Pharmaceuticals (APLS) Trades by Mario Gabelli

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 +21,000 New Buy 21,000 $40.23

Mario Gabelli's Apellis Pharmaceuticals Investment FAQs

Mario Gabelli first purchased Apellis Pharmaceuticals, Inc. (APLS) in Q1 2026, acquiring 21,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Mario Gabelli has held Apellis Pharmaceuticals, Inc. (APLS) for 1 quarters since Q1 2026.

Mario Gabelli's largest addition to Apellis Pharmaceuticals, Inc. (APLS) was in Q1 2026, adding 21,000 shares worth $844,830.

According to the latest 13F filing for Q1 2026, Mario Gabelli's firm, Gamco Investors, Inc. Et Al, owns 21,000 shares of Apellis Pharmaceuticals, Inc. (APLS), valued at approximately $844,830.

As of the Q1 2026 filing, Apellis Pharmaceuticals, Inc. (APLS) represents approximately 0.01% of Mario Gabelli's publicly disclosed stock portfolio, making it one of their key holdings.

Mario Gabelli's peak holding in Apellis Pharmaceuticals, Inc. (APLS) was 21,000 shares, as reported at the end of Q1 2026.